MCID: TNG007
MIFTS: 52

Tongue Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Smell/Taste diseases

Aliases & Classifications for Tongue Carcinoma

Summaries for Tongue Carcinoma

MalaCards based summary : Tongue Carcinoma, also known as tongue cancer, is related to tonsil cancer and tongue squamous cell carcinoma. An important gene associated with Tongue Carcinoma is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Nicotine and Central Nervous System Stimulants have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and tonsil, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Tongue Carcinoma

Diseases related to Tongue Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 319)
# Related Disease Score Top Affiliating Genes
1 tonsil cancer 30.7 TP53 NOTCH1 CDH1
2 tongue squamous cell carcinoma 30.7 VEGFA TP53 NOTCH1 MTDH MMP9 MMP2
3 oral cancer 30.5 TP53 PTGS2 MMP9 MMP2 MMP1 CDKN1A
4 oropharynx cancer 30.4 TP53 NOTCH1 CDH1
5 periodontitis, chronic 30.3 MMP8 MMP1
6 papilloma 30.2 VEGFA TP53 PTGS2 CDKN1A
7 oral squamous cell carcinoma 30.1 VEGFA TP53 MMP9 MMP2 MALAT1 CDH1
8 endometriosis 30.1 VEGFA PTGS2 MMP2 MMP1
9 rhabdomyosarcoma 30.1 VEGFA TP53 MMP2 CDKN1A CCNB1 BCL2L1
10 gastric ulcer 30.0 TP53 PTGS2 MMP9
11 adenoid cystic carcinoma 30.0 VEGFA TP53 NOTCH1 MMP9 CDH1
12 pulmonary emphysema 29.9 VEGFA MMP9 MMP8 MMP2 MMP1
13 periodontitis 29.9 PTGS2 MMP9 MMP8 MMP2 MMP1
14 leukemia, acute myeloid 29.8 VEGFA TP53 NOTCH1 MALAT1 CDKN1A CDH1
15 nasopharyngeal carcinoma 29.7 VEGFA TP53 MMP9 MMP2 MALAT1 CDH1
16 squamous cell carcinoma 29.7 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
17 squamous cell carcinoma, head and neck 29.6 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1
18 cervical cancer 29.6 TP53 PTGS2 NOTCH1 MMP2 MALAT1 CDKN1A
19 renal cell carcinoma, nonpapillary 29.6 VEGFA TP53 MMP9 MMP2 MALAT1 CDH1
20 lung cancer susceptibility 3 29.5 VEGFA TP53 PTGS2 MMP9 MMP2 MALAT1
21 esophageal cancer 29.5 VEGFA TP53 PTGS2 MMP9 MMP2 MALAT1
22 rheumatoid arthritis 29.5 VEGFA PTGS2 MMP9 MMP8 MMP2 MMP1
23 melanoma 29.3 VEGFA TP53 MTDH MMP9 MMP2 MMP1
24 colorectal cancer 28.6 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
25 breast cancer 28.5 VEGFA TP53 PTGS2 NOTCH1 MTDH MMP9
26 splenic diffuse red pulp small b-cell lymphoma 10.5 TP53 NOTCH1
27 vulvar intraepithelial neoplasia 10.5 TP53 CDH1
28 actinic cheilitis 10.5 TP53 CDKN1A
29 sarcomatoid transitional cell carcinoma 10.5 TP53 CDH1
30 invasive bladder transitional cell carcinoma 10.5 TP53 NOTCH1 CDKN1A
31 esophagus verrucous carcinoma 10.5 TP53 CDH1
32 dentin caries 10.5 MMP8 MMP20 MMP2
33 pediatric angiosarcoma 10.5 VEGFA TP53
34 cystadenocarcinoma 10.5 VEGFA TP53 CDKN1A
35 human papillomavirus infectious disease 10.5 TP53 CDKN1A
36 apocrine adenosis of breast 10.5 TP53 BCL2L1
37 keratoacanthoma 10.5 TP53 CDKN1A CDH1
38 skin papilloma 10.5 TP53 PTGS2 CDKN1A
39 esophagus adenocarcinoma 10.5 TP53 PTGS2 CDH1
40 colonic benign neoplasm 10.5 TP53 PTGS2 CDH1
41 tendinopathy 10.5 MMP8 MMP1
42 nodular regenerative hyperplasia 10.5 NOTCH1 JAG1
43 pancreatic ductal carcinoma 10.4 VEGFA TP53 CDH1
44 ovary adenocarcinoma 10.4 VEGFA TP53 CDH1
45 cardiovascular organ benign neoplasm 10.4 VEGFA TP53 NOTCH1
46 ovarian clear cell carcinoma 10.4 VEGFA TP53 CDKN1A
47 pre-malignant neoplasm 10.4 VEGFA TP53 CDH1
48 cervical squamous cell carcinoma 10.4 VEGFA TP53 MMP2 CDH1
49 serous cystadenocarcinoma 10.4 VEGFA TP53 MMP2 CDKN1A
50 differentiated thyroid carcinoma 10.4 VEGFA TP53 MMP2 BCL2L1

Graphical network of the top 20 diseases related to Tongue Carcinoma:



Diseases related to Tongue Carcinoma

Symptoms & Phenotypes for Tongue Carcinoma

MGI Mouse Phenotypes related to Tongue Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 BCL2L1 CDH1 CDKN1A JAG1 LGALS3 MMP1
2 cardiovascular system MP:0005385 10.27 CDH1 CDKN1A JAG1 LGALS3 MMP2 MMP8
3 cellular MP:0005384 10.22 BCL2L1 CDH1 CDKN1A JAG1 LGALS3 MMP9
4 immune system MP:0005387 10.22 BCL2L1 CDH1 CDKN1A LGALS3 MMP1 MMP2
5 digestive/alimentary MP:0005381 10.11 CDH1 CDKN1A JAG1 LGALS3 MMP9 NOTCH1
6 integument MP:0010771 10.11 BCL2L1 CDH1 CDKN1A JAG1 LGALS3 MMP9
7 neoplasm MP:0002006 9.97 BCL2L1 CDH1 CDKN1A LGALS3 MMP1 MMP2
8 liver/biliary system MP:0005370 9.92 CDKN1A JAG1 LGALS3 MTDH NOTCH1 PTGS2
9 muscle MP:0005369 9.86 CDKN1A JAG1 MMP2 MMP9 NOTCH1 PTGS2
10 renal/urinary system MP:0005367 9.61 CCNB1 CDKN1A JAG1 LGALS3 MMP9 NOTCH1
11 respiratory system MP:0005388 9.23 CDKN1A LGALS3 MMP2 MMP9 NOTCH1 PTGS2

Drugs & Therapeutics for Tongue Carcinoma

Drugs for Tongue Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2 Central Nervous System Stimulants Phase 4
3 Neurotransmitter Agents Phase 4
4 Nicotinic Agonists Phase 4
5 Cholinergic Agents Phase 4
6
Aldesleukin Approved Phase 3 110942-02-4, 85898-30-2
7
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
8
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
9
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
10
Promethazine Approved, Investigational Phase 3 60-87-7 4927
11
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
12 Anti-HIV Agents Phase 3
13 Interleukin-2 Phase 3
14 Anti-Retroviral Agents Phase 3
15 Hypnotics and Sedatives Phase 3
16 Antidepressive Agents Phase 3
17 Psychotropic Drugs Phase 3
18
Histamine Phosphate Phase 3 51-74-1 65513
19 Histamine Antagonists Phase 3
20 Antidepressive Agents, Tricyclic Phase 3
21 Muscarinic Agonists Phase 2, Phase 3
22
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
23
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
24
Indinavir Approved Phase 2 150378-17-9 5362440
25
Zinc oxide Approved Phase 2 1314-13-2
26
Zinc Approved, Investigational Phase 2 7440-66-6 32051
27
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
28
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
29
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
30 Raspberry Approved Phase 1, Phase 2
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
33
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
34
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
35
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
36
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
37
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
38
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
39
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
40
leucovorin Approved Phase 2 58-05-9 6006
41
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
42
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
43
Saracatinib Investigational Phase 2 379231-04-6
44 Cytochrome P-450 CYP3A Inhibitors Phase 2
45 Cytochrome P-450 Enzyme Inhibitors Phase 2
46 HIV Protease Inhibitors Phase 2
47
protease inhibitors Phase 2
48 Anesthetics Phase 2
49 Protective Agents Phase 2
50 Radiation-Protective Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
3 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
4 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
5 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
6 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
7 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
8 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
9 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
10 A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
11 Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Unknown status NCT02985255 Phase 2 Docetaxel;Cisplatin;5FU
12 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Completed NCT02849379 Phase 1, Phase 2
13 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
14 A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx Completed NCT01084083 Phase 2 Paclitaxel;Cisplatin
15 Phase I/II Study of Induction Chemotherapy With Weekly RAD001, Carboplatin and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
16 A Phase II Study of Radiotherapy (IMRT) + Cisplatin + Bevacizumab for Patients With Stage III/IV Head and Neck Cancers Completed NCT00423930 Phase 2 cisplatin
17 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
18 Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF)for Squamous Cell Carcinoma of the Oropharynx That is Operable Stage III-IV Completed NCT00665392 Phase 2 cisplatin;docetaxel;fluorouracil;Cetuximab
19 Phase II Study Evaluating Radiotherapy-chemotherapy and Cetuximab in Patients With Histologically Proven Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx and With a Poor Prognosis After Complete Surgical Resection Completed NCT00875849 Phase 2 cisplatin
20 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
21 A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma Completed NCT00851877 Phase 1, Phase 2 Cisplatin;Nab-Paclitaxel
22 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Completed NCT03008330 Phase 1, Phase 2
23 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Completed NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
24 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
25 A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer Completed NCT01195922 Phase 1, Phase 2 Sirolimus
26 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
27 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
28 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
29 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
30 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
31 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
32 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
33 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
34 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
35 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
36 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
37 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
38 Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
39 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Recruiting NCT03602079 Phase 1, Phase 2 A166
40 Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
41 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
42 DORA: A Phase I and Randomized Phase II Study of Docetaxel and RAD001 (Everolimus) in Advanced/Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Terminated NCT01313390 Phase 1, Phase 2 docetaxel;everolimus
43 A Phase II Study of Tongue Conservation Surgery for Advanced Oral Tongue Cancer: Induction Chemotherapy, Followed by Tongue Conservation Surgery and Postoperative Chemoradoitherapy Terminated NCT03161548 Phase 2 Induction chemotherapy
44 Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin Versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer Withdrawn NCT01953952 Phase 2 cisplatin
45 A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC) Withdrawn NCT01674374 Phase 2 Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
46 Adjuvant p53 Peptide Loaded DC-Based Therapy for Subjects With Squamous Cell Cancer of the Head and Neck (A Phase I Safety and Immunogenicity Trial) Completed NCT00404339 Phase 1
47 B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
48 Implementation of an Intraoral Stent in Radiotherapy of Tongue Cancer Completed NCT04337853 Phase 1
49 Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) Completed NCT01334177 Phase 1 TLR8 agonist VTX-2337
50 A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT02035527 Phase 1 sorafenib tosylate;cisplatin;docetaxel

Search NIH Clinical Center for Tongue Carcinoma

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Carcinoma

Anatomical Context for Tongue Carcinoma

MalaCards organs/tissues related to Tongue Carcinoma:

40
Tongue, Lymph Node, Tonsil, Endothelial, Brain, Liver, Thyroid

Publications for Tongue Carcinoma

Articles related to Tongue Carcinoma:

(show top 50) (show all 2188)
# Title Authors PMID Year
1
Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. 61 54
19331169 2009
2
Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. 61 54
18253113 2008
3
Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. 61 54
17611661 2007
4
NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. 61 54
17005413 2006
5
Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma. 54 61
16767431 2006
6
Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. 61 54
16331606 2006
7
[Effects of arsenic trioxideon the cell apoptosis and hTERT mRNA of human tongue cancer cells]. 61 54
16285558 2005
8
The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. 54 61
15289890 2004
9
Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. 61 54
14730689 2004
10
Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. 61 54
14977084 2004
11
MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. 54 61
12454097 2002
12
Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. 61 54
11900224 2002
13
A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. 54 61
11206273 2001
14
Inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line. 54 61
11315101 2000
15
p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years. 54 61
10645402 1999
16
Tenascin: growth and adhesion modulation--extracellular matrix degrading function: an in vitro study. 61 54
8736172 1996
17
Expression of the cell-cell adhesion molecule E-cadherin in tongue carcinoma cell lines. 54 61
7829949 1994
18
Circulating prolactin and tumoral prolactin receptors in men with tongue cancer: a preliminary study. 61 54
8181582 1994
19
Biopsy quality is essential for preoperative prognostication in oral tongue cancer. 61
33320967 2021
20
Magnetic resonance imaging differentiates locoregional flaps from free flaps after reconstructive surgical treatment of tongue cancer. 61
32855103 2021
21
Pedicled Islanded Nasolabial Flap Tunneled Under Mandible for Tongue Reconstruction. 61
33584050 2021
22
Myocardial Metastasis of Tongue Cancer: A Rare Localization. 61
33574215 2021
23
Medial clavicle fracture with bone destruction after radical neck dissection combined with postoperative chemotherapy for secondary cervical lymph node metastasis of tongue cancer: a case report. 61
33576918 2021
24
Depth of invasion determined by magnetic resonance imaging in tongue cancer can be a predictor of cervical lymph node metastasis. 61
32800495 2021
25
The role of electrochemotherapy with intratumoral bleomycin for early tongue carcinoma. 61
33591860 2021
26
Patient-Reported Quality of Life After Resection With Primary Closure for Oral Tongue Carcinoma. 61
32379355 2021
27
Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention. 61
33247317 2021
28
High expression of Notch2 drives tongue squamous cell carcinoma carcinogenesis. 61
33382997 2021
29
The mutational landscape of early- and typical-onset oral tongue squamous cell carcinoma. 61
33146897 2021
30
Salvage Surgery for Recurrent Tongue Cancer With Contralateral Neck Metastasis. 61
32971059 2021
31
The emergence of oral cavity cancer and the stabilization of oropharyngeal cancer: Recent contrasting epidemics in the South Korean population. 61
33595858 2021
32
Septic pulmonary emboli caused by Tsukamurella inchonensis: A case report. 61
33036892 2021
33
The Histopathology of Oral Cancer Pain in a Mouse Model and a Human Cohort. 61
33030108 2021
34
Novel system in vitro of classifying oral carcinogenesis based on feature extraction for gray-level co-occurrence matrix using scanned laser pico projector. 61
33528670 2021
35
Head and neck surgery during COVID-19. 61
33552941 2021
36
EZB-ICR Cell Line: A New Established and Characterized Oral Squamous Cell Carcinoma Cell Line From Tongue. 61
33507685 2021
37
KLF7 is associated with poor prognosis and regulates migration and adhesion in tongue cancer. 61
33393169 2021
38
HPV+ve/-ve oral-tongue cancer stem cells: A potential target for relapse-free therapy. 61
33129107 2021
39
The occult nodal metastasis rate of early tongue cancer (T1-T2): A protocol for a systematic review and meta-analysis. 61
33546063 2021
40
Can MRI-derived depth of invasion predict nodal recurrence in oral tongue cancer? 61
33469800 2021
41
Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis. 61
33290780 2021
42
Functional Swallow-Related Outcomes Following Transoral Robotic Surgery for Base of Tongue Carcinoma. 61
33492468 2021
43
Carcinostatic effects of alkanoyl ascorbate plus platinum nano-colloid and stabilization of the esterolytically resultant ascorbate by hydrogen. 61
33387361 2021
44
Operative tactics in floor of mouth and tongue cancer resection - the importance of imaging and planning. 61
33143945 2021
45
Compartmental Surgery for Oral Tongue Cancer: Objective and Subjective Functional Evaluation. 61
32239760 2021
46
Correction to: Radiological approach for the newly incorporated T staging factor, depth of invasion (DOI), of the oral tongue cancer in the 8th edition of American Joint Committee on Cancer (AJCC) staging manual: assessment of the necessity for elective neck dissection. 61
33025337 2021
47
Comparison of nomogram with machine learning techniques for prediction of overall survival in patients with tongue cancer. 61
33142259 2021
48
In-vivo tongue stiffness measured by aspiration: Resting vs general anesthesia. 61
33276256 2021
49
Adjuvant contralateral neck irradiation for oral cavity cancer - A systematic review and meta-analysis. 61
33476968 2021
50
Oral Organoids: Progress and Challenges. 61
33478323 2021

Variations for Tongue Carcinoma

Expression for Tongue Carcinoma

Search GEO for disease gene expression data for Tongue Carcinoma.

Pathways for Tongue Carcinoma

Pathways related to Tongue Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 VEGFA TP53 PTGS2 MMP9 MMP8 MMP2
2
Show member pathways
13.55 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP8
3
Show member pathways
13.34 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1
4
Show member pathways
12.97 VEGFA TP53 PTGS2 NOTCH1 JAG1 CDKN1A
5
Show member pathways
12.94 VEGFA TP53 PTGS2 CDKN1A CCNB1 BCL2L1
6
Show member pathways
12.87 VEGFA TP53 MMP9 CDKN1A CDH1 BCL2L1
7
Show member pathways
12.75 TP53 NOTCH1 JAG1 CDKN1A CDH1 BCL2L1
8
Show member pathways
12.74 MMP9 MMP8 MMP20 MMP2 MMP1 CDH1
9
Show member pathways
12.62 TP53 NOTCH1 MMP9 MMP2 JAG1 CDKN1A
10 12.62 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
11 12.49 VEGFA TP53 PTGS2 NOTCH1 MMP9 CDKN1A
12
Show member pathways
12.37 TP53 CDKN1A CCNB1 BCL2L1
13 12.35 TP53 CDKN1A CDH1 CCNB1
14 12.29 VEGFA TP53 MMP9 MMP2 CDKN1A
15 12.26 TP53 MMP9 CDKN1A BCL2L1
16 12.15 VEGFA TP53 MMP1 CDH1
17 12.09 VEGFA TP53 MMP9 MMP2
18 12.07 TP53 MMP2 CDKN1A CCNB1
19 12.02 MTDH MMP9 MMP2 CDH1
20 12 TP53 PTGS2 MMP9 LGALS3
21 11.86 TP53 PTGS2 CDKN1A BCL2L1
22
Show member pathways
11.85 MMP9 MMP8 MMP20 MMP2 MMP1
23 11.83 TP53 CDKN1A CCNB1
24
Show member pathways
11.82 TP53 CDKN1A CCNB1
25 11.79 TP53 MMP1 CDKN1A
26 11.79 TP53 MTDH MMP9 CCNB1
27 11.78 PTGS2 NOTCH1 MMP9 MMP2 JAG1
28 11.77 MMP9 MMP2 CDH1
29 11.77 PTGS2 CDKN1A CCNB1
30 11.74 NOTCH1 JAG1 CDKN1A
31 11.73 TP53 CDKN1A BCL2L1
32 11.71 VEGFA TP53 MMP2 CDKN1A
33 11.68 MMP9 MMP2 LGALS3
34 11.66 VEGFA TP53 MMP9 MMP2 MMP1 CDKN1A
35 11.64 MMP9 MMP2 MMP1
36 11.61 VEGFA PTGS2 MMP9 CDKN1A
37 11.61 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1
38
Show member pathways
11.57 VEGFA PTGS2 MMP9 MMP2 MMP1
39 11.53 VEGFA PTGS2 CDKN1A
40 11.52 TP53 MMP2 CDKN1A BCL2L1
41 11.51 VEGFA TP53 PTGS2 MMP1 CDKN1A BCL2L1
42 11.5 TP53 MMP1 CDKN1A
43 11.49 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1
44 11.42 MMP9 MMP1 LGALS3
45 11.36 VEGFA TP53 PTGS2 BCL2L1
46 11.35 MMP9 MMP2 MMP1
47 11.3 TP53 CDKN1A CCNB1
48 11 VEGFA NOTCH1 JAG1
49 10.96 VEGFA NOTCH1 JAG1
50 10.79 TP53 CDKN1A BCL2L1

GO Terms for Tongue Carcinoma

Cellular components related to Tongue Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA NOTCH1 MMP9 MMP8 MMP20 MMP2
2 adherens junction GO:0005912 9.46 VEGFA NOTCH1 JAG1 CDH1
3 extracellular matrix GO:0031012 9.1 VEGFA MMP9 MMP8 MMP20 MMP2 MMP1

Biological processes related to Tongue Carcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.02 VEGFA TP53 PTGS2 MTDH MMP9 CDKN1A
2 response to drug GO:0042493 10 TP53 PTGS2 CDKN1A CDH1 CCNB1
3 angiogenesis GO:0001525 9.96 VEGFA PTGS2 NOTCH1 MMP2 JAG1
4 regulation of cell proliferation GO:0042127 9.93 TP53 PTGS2 NOTCH1 JAG1
5 negative regulation of gene expression GO:0010629 9.93 VEGFA TP53 NOTCH1 MMP8 CDKN1A CCNB1
6 in utero embryonic development GO:0001701 9.91 VEGFA TP53 NOTCH1 CCNB1 BCL2L1
7 response to toxic substance GO:0009636 9.83 CDKN1A CDH1 CCNB1
8 response to organic substance GO:0010033 9.83 PTGS2 CDKN1A CDH1
9 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.8 TP53 CDKN1A CCNB1
10 extracellular matrix organization GO:0030198 9.8 MMP9 MMP8 MMP20 MMP2 MMP1 CDH1
11 positive regulation of protein complex assembly GO:0031334 9.79 VEGFA MMP1 LGALS3
12 embryo implantation GO:0007566 9.78 PTGS2 MMP9 MMP2
13 cellular response to hypoxia GO:0071456 9.77 VEGFA TP53 PTGS2 MALAT1 CCNB1
14 cellular response to gamma radiation GO:0071480 9.75 TP53 CDKN1A BCL2L1
15 endodermal cell differentiation GO:0035987 9.74 MMP9 MMP8 MMP2
16 tissue regeneration GO:0042246 9.7 NOTCH1 CDKN1A CCNB1
17 cardiac septum morphogenesis GO:0060411 9.67 TP53 NOTCH1 JAG1
18 response to muramyl dipeptide GO:0032495 9.65 NOTCH1 JAG1
19 Notch signaling involved in heart development GO:0061314 9.65 NOTCH1 JAG1
20 tube formation GO:0035148 9.64 VEGFA NOTCH1
21 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.64 VEGFA NOTCH1
22 coronary artery morphogenesis GO:0060982 9.63 VEGFA NOTCH1
23 signal transduction by p53 class mediator GO:0072331 9.61 TP53 CDKN1A
24 regulation of neuroinflammatory response GO:0150077 9.61 PTGS2 MMP9 MMP8
25 distal tubule development GO:0072017 9.59 NOTCH1 JAG1
26 cardiac vascular smooth muscle cell development GO:0060948 9.58 VEGFA NOTCH1
27 cellular response to UV-A GO:0071492 9.58 MMP9 MMP2 MMP1
28 positive regulation of cardiac epithelial to mesenchymal transition GO:0062043 9.55 NOTCH1 JAG1
29 extracellular matrix disassembly GO:0022617 9.55 MMP9 MMP8 MMP20 MMP2 MMP1
30 coronary vein morphogenesis GO:0003169 9.54 VEGFA NOTCH1
31 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.43 VEGFA TP53 NOTCH1
32 collagen catabolic process GO:0030574 9.35 MMP9 MMP8 MMP20 MMP2 MMP1
33 cytokine-mediated signaling pathway GO:0019221 9.23 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1

Molecular functions related to Tongue Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.8 TP53 MMP9 MMP8 MMP20 MMP2 MMP1
2 peptidase activity GO:0008233 9.77 MMP9 MMP8 MMP20 MMP2 MMP1
3 serine-type endopeptidase activity GO:0004252 9.56 MMP9 MMP8 MMP2 MMP1
4 endopeptidase activity GO:0004175 9.46 MMP9 MMP8 MMP2 MMP1
5 metallopeptidase activity GO:0008237 9.35 MMP9 MMP8 MMP20 MMP2 MMP1
6 metalloendopeptidase activity GO:0004222 9.02 MMP9 MMP8 MMP20 MMP2 MMP1

Sources for Tongue Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....